Study of Immune and Anxiety-Depression Features in Patients with Unstable Angina and Coronary Heart Disease

What this Trial Is About

Researchers are studying the connection between coronary heart disease, specifically unstable angina pectoris, and anxiety-depressive syndrome. The trial includes 202 patients, with 160 having unstable angina and 42 having stable angina as a control group. The study aims to explore how these heart conditions and mental health issues might influence each other, using established diagnostic criteria and scales to assess anxiety, depression, and cognitive function. Participants undergo blood draws in the morning after fasting for 8-12 hours to measure levels of cytokines TNF-b1, IL-1b2, IL-4, IL-10 using enzyme-linked immunosorbent assay ELISA and uric acid levels. Patients with unstable angina receive conventional therapy including nitrates, beta-blockers, ACE inhibitors or sartans, antiplatelet agents, and statins. Those with elevated uric acid are treated with Febuxostat, and patients with anxiety-depressive syndrome receive Divase syndrome, a neurotropic and antioxidant medication. Throughout the study, participants complete anxiety and depression assessments using the Hospital Anxiety and Depression Scale and the Spielberger-Khanin Anxiety Scale. Researchers track cytokine and uric acid levels from 2019 to 2027 to understand the immune and biochemical profiles linked to these conditions. The study also monitors cognitive functions and allows patients to withdraw at any time, with ongoing evaluation to support patient safety and well-being.

Unstable Angina Pectoris in Comorbidity With Anxiety-depressive Syndrome